Anbio Biotechnology (NNNN) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Anbio Biotechnology had a P/E ratio of 206.11, return on equity of 27.1% (up from 14.8%), a current ratio of 344.31 (up from 10.71) and return on assets of 14.7% (up from 7.2%). A current ratio of 344.31 means current assets exceed current liabilities.

Anbio Biotechnology Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Valuation Ratios
P/E Ratio	206.11	-	-	-	-
P/S Ratio	152.63	-	-	-	-
P/B Ratio	43.77	-	-	-	-
Price/Tangible Book	43.77	-	-	-	-
Enterprise Value Ratios
EV/Revenue	151.08	-	-	-	-
EV/EBIT	226.50	-	-	-	-
Profitability & Returns
Return on Equity (ROE)	27.05%	14.83%	16.47%	132.75%	-
Return on Assets (ROA)	14.66%	7.18%	8.23%	67.52%	-
Return on Capital Employed (ROCE)	19.10%	11.60%	13.20%	81.30%	96.80%
Leverage & Solvency Ratios
Liquidity Ratios
Current Ratio	344.31	10.71	15.86	9.88	2.07
Quick Ratio	177.13	7.41	11.65	6.14	2.06
Efficiency Ratios
Asset Turnover	0.35	0.47	0.45	2.50	-
Yield & Distribution Ratios
Earnings Yield	0.49%	-	-	-	-
Buyback Yield	-3.26%	-97.30%	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Dec 31, 2025. Data sources and methodology

Frequently Asked Questions About Anbio Biotechnology Financial Ratios

What is Anbio Biotechnology's P/E ratio?

Anbio Biotechnology's P/E ratio was 206.11 for fiscal 2025 (period ended Dec 31, 2025).

What is Anbio Biotechnology's return on equity?

Anbio Biotechnology's return on equity (ROE) was 27.1% for fiscal 2025 (period ended Dec 31, 2025). It was 14.8% a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition